From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ball-and-stick model of the 5-APB molecule
Systematic (IUPAC) name
Clinical data
Legal status
  • Class B (UK)
CAS Registry Number 286834-81-9 N
ATC code None
PubChem CID: 9837232
ChemSpider 8012953 YesY
Synonyms 1-Benzofuran-5-ylpropan-2-amine
Benzo fury
Chemical data
Formula C11H13NO
Molecular mass 175.23 g/mol
 N (what is this?)  (verify)

5-APB (5-(2-aminopropyl)benzofuran, 1-benzofuran-5-ylpropan-2-amine, benzofury) is a triple monoamine reuptake inhibitor with Ki values of 180, 265 and 811 nM for NET, DAT and SERT respectively as well as being a potent agonist for the 5-HT2A and 5-HT2B receptors (Ki of 14nM at 5-HT2B).[1][2] This agonism for 5-HT2B makes it likely that 5-APB would be cardiotoxic with long term use, as seen in other 5-HT2B agonists such as fenfluramine and MDMA. The subjective effects and structure-activity relationship suggest that 5-APB is also a monoamine releasing agent.[citation needed]

5-APB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is 10% more potent by mass and doses should be adjusted accordingly.

5-APB is also an agonist of the 5-HT2C receptor [3] as well as a triple monoamine reuptake inhibitor.[2] It has been sold as a designer drug since 2010.[4]


A forensic standard of 5-APB is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[5] The US Department of Justice and DEA have also conducted studies concerning the detection of 5-APB.[6]


Users describe effects as euphoric. Largely, effects reported were similar to that of the drug MDA but not as strong.[citation needed] Recreational use of 5-APB has been associated with death in combination with other drugs.[7][8]


On March 5, 2014 the UK Home Office announced that 6-APB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.[9]

See also[edit]


  1. ^ Dawson P, Opacka-Juffry J, Moffatt JD, Daniju Y, Dutta N, Ramsey J, Davidson C. The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Progress in Neuropsychopharmacology and Biological Psychiatry. 2014 Jan 3;48:57-63. doi: 10.1016/j.pnpbp.2013.08.013. PMID 24012617 edit
  2. ^ a b Iversen, L.; Gibbons, S.; Treble, R.; Setola, V.; Huang, X. P.; Roth, B. L. (2012). "Neurochemical profiles of some novel psychoactive substances". European Journal of Pharmacology. doi:10.1016/j.ejphar.2012.12.006.  edit
  3. ^ US patent 7045545, Karin Briner et al, "Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists", published 2000-01-19, issued 2006-16-03 
  4. ^ EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA
  5. ^ Southern Association of Forensic Scientists, http://forendex.southernforensic.org/index.php/detail/index/1135
  6. ^ USDOJ/DEA, http://www.justice.gov/dea/pr/microgram-journals/2011/mj8-2_62-74.pdf
  7. ^ "UCSD student dies of drug overdose after on-campus music festival". Los Angeles Times. August 20, 2014. 
  8. ^ "The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat". Prog Neuropsychopharmacol Biol Psychiatry 48: 57–63. Jan 3, 2014. doi:10.1016/j.pnpbp.2013.08.013. PMID 24012617. 5-APB ... has been implicated in 10 recent drug-related deaths in the UK 
  9. ^ UK Home Office (2014-03-05). "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Government. Retrieved 2014-03-11.